AbbieVie

Recent Articles

RELATED ARTICLES

  1. The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising.
    BeiGene still bleeding red ink despite blockbuster drug
    BGNE.US 6160.HK 688235.SHG
  2. BeiGene’s aggressive expansion brings revenue jolt
    BGNE.US 6160.HK 688235.SHG
  3. Akeso marks profit milestone with swift rights issue
    9926.HK
  4. Test results for new cancer drug take Akeso investors on wild ride
    9926.HK
  5. Hutchmed scores U.S. success with cancer drug, but profits still dip
    HCM.US 0013.HK
  6. Clinical trials come up short again for Alphamab Oncology
    9966.HK
  7. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva